Protein and Peptide Microarray

For education only

This guide cannot diagnose a condition or recommend a personal treatment plan. Discuss medical questions with a qualified professional.

By Jesharee Sundaram, MBA

Protein and peptide microarrays, the emerging tools for proteomics and clinical assays, are high-throughput methods that track binding events and activities, and decide the function of proteins on a large scale. Microarrays find their place in epitope mapping and serodiagnostic applications.

Protein microarray

Protein microarrays are classified as 1) analytical protein microarrays 2) functional proteins, and 3) reverse-phase protein microarrays, based on their application.

Analytical protein microarray

Antibody array is the most representative model of analytical protein microarrays. Using direct protein labeling, proteins are found after antibody capture. The sandwich assay format employs two different antibodies to find the targeted protein, allowing differentiation between two similar blood samples, for example.

Functional protein microarray

This type of array is created by use of proteins that are purified individually. The main function of this kind of array is to study the different biochemical properties of proteins. This may include the study of binding activities of protein as well as enzyme–substrate relationships. After the first effort that used protein kinases in yeast to determine the substrate specificity, many significant biological discoveries have since happened.

Reverse-phase protein array (RPPA)

RPPA is a type of microarray that allows testing of different probes of lysate samples that help in identifying specifically, the various proteins in it. Initially, these kinds of microarrays were used in monitoring prostate cancer patients to identify historical changes.

Applications

Various types of protein binding properties are detected by developing new assays to characterize protein-DNA and for protein–peptide interaction. Test ligands are directly or indirectly labeled with fluorescent dyes during the analysis of protein–protein and protein–lipid interactions.

Protein–small molecule interaction is used to discover new drug molecules and drug targets, while protein–glycan interaction finds the new role of protein glycosylation in mitochondrial protein function and localization. Since antibodies are widely used in proteomic studies, protein microarrays are helpful in profiling the monoclonal antibody specificity.

An important mechanism to directly control protein activity is the protein posttranslational modification (PTM). Protein application to phosphorylation finds the substrate specificity of the yeast kinome and discovers new tyrosine phosphorylation activity; ubiquitylation controls almost all sorts of cellular events in eukaryotes. Protein acetylation—histone acetylation and deacetylation promise to be important regulators of chromatin structure and transcription, while S-nitrosylation has effects on an extensive range of proteins involved in several cellular processes.

Protein microarrays are very useful in clinical research as they aid in developing highly sensitive and specific diagnostic and testing tools. Studies have found positive results for broad-spectrum antiviral development. Protein microarrays help to find a powerful biomarker to expedite detection or diagnosis of autoimmune diseases for severe acute respiratory syndrome (SARS), inflammatory bowel diseases (IBDs), and profile serological responses following bacterial and viral infection.

Library construction and microarray fabrication are two important factors to be considered for the success of microarray-based screening.

Peptide microarray

The well established “solid phase peptide synthesis” (SPPS), along with the comparatively easier fabrication of the corresponding microarrays, characterize peptide libraries as a very significant source of microarray applications. The idea of split-and-pool synthesis allowed creating large peptide libraries that consist of a huge number of molecules in very few short steps. A classic representative of peptide microarrays are kinase assays.

Knowledge-based peptide libraries

Knowledge-based libraries can be defined as libraries that are constructed using already known peptide sequences. These peptide libraries are mostly used in investigating proteins with known substrate or interacting partners. They can be constructed by using common combinatorial concepts such as positional scanning, alanine scanning, and amino acid deletion.

To discover peptide substrates with improved binding activity, positional-scanning libraries are used. They are constructed by the introduction of mutation within the known binding sites of the target protein at definite positions.

This can be used in alanine-scanning libraries in which the alanine residue replaces every amino acid in the peptide. It probes the contribution of each amino acid. Deletion libraries are designed by the systematic removal of flanking residues from the parent peptide. These libraries are used in determining the minimum sequence of a peptide needed for their normal activities to take place as usual. The routine investigation of amino acid residues that are essential for molecular interactions is done by the peptide arrays made of this kind of libraries.

Combinatorial libraries

When the target protein’s substrate is unknown, combinatorial peptide library-based microarrays are suitable. To reduce the synthesis of a large number of peptides, a semi-random combinatorial approach is used. This also helps in finding new peptide substrates and learning about proteins that are not known. Peptide microarrays are effective in categorizing known and unknown interactions between protein and peptide and offer possible tools to create peptide-based probes for functional annotation of RNAs in cells. Epigenetic modifications may have greater control on various human diseases.

Outlook

The high cost of instruments and library resources make it difficult for researchers to gain benefits from microarrays. However, peptide microarrays are much more consistent and less costly than protein microarrays. The different forms of microarray technologies, such as protein microarray and peptide microarray are analytical tools for proteomics research that facilitate drug discovery and have diagnostic applications.

Sources:

Helpful context for this guide

Source-derived material selected through this article’s indexed topics.

Related questions

01In your work, you've explored the molecular mechanisms underlying neuronal sensitization in sensory neurons. How does this relate to your broader research on axon biology, and what are the potential clinical implications?

At its core, pain involves sensory neurons that extend axons from their cell bodies into peripheral tissues and the spinal cord. Understanding these sensory terminals, especially their responses under various conditions such as inflammation, is pivotal. Our Axon-RNA-centric approach allows us to detect RNA changes and leverage them to alter sensitized states, providing a more accessible avenue for drug targeting.

Source: www.news-medical.net ↗

02What knowledge has your research provided, specifically regarding Alzheimer's disease?

The main protein or peptide in Alzheimer's disease patients is something called beta-amyloid. It has a 42 amino acid chain, and accumulates in the plaque between nerve cells in Alzheimer's disease patients. Beta-amyloid has been found to epimerize. Certain amino acids epimerize in the beta-amyloid at specific locations, and it turns out those amino acids are mainly aspartic acid and serine. There was no good way to analyze for such aberrations in beta-amyloid until now, and we have found a number of techniques that not only detect it, but can point out exactly where, within the beta-amyloid chain, the aberration is occurring and if there are more aberrations in Alzheimer's patients than in normal people. Image Credit:Shutterstock/Tavarius

Source: www.news-medical.net ↗

03How does the zwitterionic form of an amino acid relate to the pI?

When the pH is exactly at the pKa value, a buffer arises in which the deprotonated and protonated amino acids exist in equilibrium. For example, when the pH = 2.34 (pKa of glycine), the solution comprises of 50% neutral molecules in which the carboxyl is deprotonated, and 50% positive molecules where the carboxyl is protonated. This pH produces the carboxyl buffer zone. If the pH s increased to that of the pKa of the amino group (9.60), another buffer is produced where there is an equilibration between the protonated neutral zwitterion and the deprotonated negative amino acid. The isoelectric point can, therefore, be approximated by averaging the two pKa values. More complex amino acids have more than two pKa values due to the presence of additional pKa values for their side chains.

Source: www.news-medical.net ↗

04In safety assessment, the consequences of being wrong are significant. How do you think about uncertainty and model limitations for safety and discovery?

Uncertainty and model limitations are critical in safety assessment. There is clearly greater potential for animal or human harm from an incorrect safety assessment than from making the wrong molecule in early discovery, although uncertainty matters in both contexts. It is important to distinguish different types of uncertainty. Aleatoric uncertainty reflects irreducible randomness in a task, while epistemic uncertainty is model-related, such as hallucinations or lack of knowledge. For LLM systems, we use multiple methods to measure consistency and we have built fact-checking approaches in which a separate LLM independently verifies the primary engine's outputs. For QSAR models, including our SAR work around seizure liability, we can use statistical metrics such as confidence intervals to quantify and communicate uncertainty. Understanding that uncertainty exists and communicating it in both safety and discovery is critical. Uncertainty metrics tell us where potential blind spots may exist in our modelling allowing us to take action to improve over time. This applies to both safety and discovery. The aim is not to pretend AI removes uncertainty, but to make uncertainty visible so scientists can make better-informed decisions. Download the Full PDF to Revisit James McDonagh's Insights on AI in Drug Safety Discovery

Source: www.news-medical.net ↗

05What are 'dancing molecules'?

Stupp and his team posited that "dancing molecules" might encourage the stubborn tissue to regenerate. Previously invented in Stupp's laboratory, dancing molecules are assemblies that form synthetic nanofibers comprising tens to hundreds of thousands of molecules with potent signals for cells. By tuning their collective motions through their chemical structure, Stupp discovered the moving molecules could rapidly find and properly engage with cellular receptors, which also are in constant motion and extremely crowded on cell membranes. Once inside the body, the nanofibers mimic the extracellular matrix of the surrounding tissue. By matching the matrix's structure, mimicking the motion of biological molecules and incorporating bioactive signals for the receptors, the synthetic materials are able to communicate with cells. "Cellular receptors constantly move around," Stupp said. "By making our molecules move, 'dance' or even leap temporarily out of these structures, known as supramolecular polymers, they are able to connect more effectively with receptors."

Source: www.news-medical.net ↗

About the author

Peptide Therapy Guide Editorial Team

Editorial team for Peptide Therapy Guide.

View all articles →

Protein microarray

Applications

Peptide microarray

Outlook

Sources:

Further Reading

Related questions

Peptide Therapy Guide Editorial Team

Protein And Peptide Microarray Based Technology Ppt | In-Depth Analysis of Industry Adoption of Protein And Peptide Microarray Based Technology Ppt | Peptide Share

Traumatic brain injuries could be healed using peptide hydrogels

What are Lipids?

Scientists discover irreversible peptide inhibitors for undruggable cancer target